GIC
SRPT icon

Generali Investments CEE’s Sarepta Therapeutics SRPT Stock Holding History

Generali Investments CEE’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81M Buy
211,850
+48,560
+30% +$918K 0.18% 141
2026
Q1 		$3.55M Buy
163,290
+26,828
+20% +$519K 0.19% 148
2025
Q4 		$2.94M Buy
136,462
+12,813
+10% +$270K 0.21% 154
2025
Q3 		$2.38M Buy
123,649
+18,323
+17% +$327K 0.18% 151
2025
Q2 		$1.8M Buy
105,326
+103,326
+5,166% +$4.41M 0.15% 177
2025
Q1 		$128K Hold
2,000
– – 0.01% 350
2024
Q4 		$243K Buy
+2,000
New +$245K 0.03% 296

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Generali Investments CEE's SRPT Position: Q2 2026 in Review

Generali Investments CEE increased its Sarepta Therapeutics (SRPT) stake by 30% in Q2 2026, buying an estimated $918K and bringing the position to 211,850 shares worth $3.81M. The position accounts for 0.18% of the portfolio, ranked #141.

Generali Investments CEE first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Generali Investments CEE held 211,850 shares of Sarepta Therapeutics worth $3.81M as of Q2 2026.
  • Generali Investments CEE bought 48,560 Sarepta Therapeutics shares in Q2 2026, an estimated $918K.
  • Sarepta Therapeutics made up 0.18% of Generali Investments CEE's portfolio in Q2 2026, its #141 holding.
  • Generali Investments CEE first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.